The frequency of circulating CD3+CTLA-4+ cells positively correlated with a poor pathologic response to neoadjuvant treatment determined by tumour regression grade using the Mandard scoring system (p = 0.04) (Fig.1S). The gene discussed is CTLA4; the disease is neoplasm.